Search Results - "Schellhammer, P F"

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy by Wright, George L., Mayer Grob, B., Haley, Cara, Grossman, Katie, Newhall, Kathy, Petrylak, Daniel, Troyer, John, Konchuba, Alice, Schellhammer, Paul F., Moriarty, Richard

“…To determine the expression of prostate-specific membrane antigen (PSMA) before and after androgen-deprivation therapy and to compare PSMA expression with…”
Get full text

Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer by McCammon, Kurt A., Kolm, Paul, Main, Brian, Schellhammer, Paul F.

“…Objectives. To determine and compare quality-of-life (QOL) evaluations from patients who received external beam radiation therapy or radical prostatectomy for…”
Get full text

Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis by Gerber, G S, Thisted, R A, Chodak, G W, Schroder, F H, Frohmuller, H G, Scardino, P T, Paulson, D F, Middleton, Jr, A W, Rukstalis, D B, Smith, Jr, J A, Ohori, M, Theiss, M, Schellhammer, P F

“…We investigated the disease-specific and metastasis-free survival rates in men with locally advanced (clinical stage T3) prostate cancer who were treated…”
Get more information

Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review by Schmitt, Brian, Wilt, Timothy J, Schellhammer, Paul F, DeMasi, Vincenzo, Sartor, Oliver, Crawford, E.David, Bennett, Charles L

“…Objectives. Combined androgen blockade with medical or surgical castration plus a nonsteroidal antiandrogen for metastatic prostate cancer has been the subject…”
Get full text

Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma by Kondylis, F I, Demirci, S, Ladaga, L, Kolm, P, Schellhammer, P F

“…Substaging of T1 bladder tumors into T1a and T1b based on invasion of the tumor superficial to and beyond the muscularis mucosa has been assigned prognostic…”
Get more information

Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures by Wright, Jr, G L, Cazares, L H, Leung, S-M, Nasim, S, Adam, B-L, Yip, T-T, Schellhammer, P F, Gong, L, Vlahou, A

“…Improving early detection, diagnosis, treatment monitoring and prognosis of cancer will require rapid and high throughput detection, identification, and…”
Get full text

Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer by Sarosdy, M F, deVere White, R W, Soloway, M S, Sheinfeld, J, Hudson, M A, Schellhammer, P F, Jarowenko, M V, Adams, G, Blumenstein, B A

“…We compare the Bard BTA (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. A…”
Get more information

Improved detection of recurrent bladder cancer using the bard bta stat test by Sarosdy, Michael F., Hudson, M'Liss A., Ellis, William J., Soloway, Mark S., White, Ralph deVere, Sheinfeld, Joel, Jarowenko, Mark V., Schellhammer, Paul F., Schervish, Ed W., Patel, Jay V., Chodak, Gerald W., Lamm, Donald L., Johnson, Robert D., Henderson, Mary, Adams, George, Blumenstein, Brent A., Thoelke, Kent R., Pfalzgraf, Randy D., Murchison, Heather A., Brunelle, Sharon L.

“…Abstract To evaluate the BTA stat Test in the detection of recurrent bladder cancer. Sensitivity and specificity were determined using frozen voided urine…”
Get full text

Conservative surgical therapy for penile and urethral carcinoma by Davis, John W, Schellhammer, Paul F, Schlossberg, Steven M

“…Objectives. Invasive penile and urethral tumors are traditionally treated with aggressive excision that requires involved organ and adjacent organ sacrifice…”
Get full text

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer: will more prove better? by Schellhammer, P F

Get more information

Determination of the reflex range and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system by VASHI, A. R, WOJNO, K. J, DOWELL, B. L, BORDEN, K. K, OESTERLING, J. E, HENRICKS, W, ENGLAND, B. A, VESSELLA, R. L, LANGE, P. H, WRIGHT, G. L, SCHELLHAMMER, P. F, WEIGAND, R. A, OLSON, R. M

“…Prostate-specific antigen (PSA) exists in the serum in two clinically important molecular forms: free PSA and PSA complexed to alpha 1-antichymotrypsin. Total…”
Get full text

Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present by Schellhammer, P.F, Moriarty, R, Bostwick, D, Kuban, D

“…Objectives. To report the overall survival for 126 patients more than 15 years after iodine-125 interstitial therapy; to report the biochemical progression…”
Get full text

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade by Schellhammer, P F, Venner, P, Haas, G P, Small, E J, Nieh, P T, Seabaugh, D R, Patterson, A L, Klein, E, Wajsman, Z, Furr, B, Chen, Y, Kolvenbag, G J

“…We determined whether decreases in prostate specific antigen (PSA) would occur after withdrawal of double-blinded antiandrogen therapy with flutamide or…”
Get more information

Endocrine effects, efficacy and tolerability of a 10.8‐mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer by Sarosdy, M F, Schellhammer, P F, Soloway, M S, Vogelzang, N J, Crawford, E D, Presti, J, Chodak, G W, Mitchell, P, Porter, L

“…Objective To determine the endocrine effects, efficacy and tolerability of a 10.8‐mg depot formulation of Zoladex™(goserelin acetate, Zeneca Pharmaceuticals,…”
Get full text

Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer by Kuban, D A, el-Mahdi, A M, Schellhammer, P F

“…This study was undertaken to assess the predictive value of pretreatment prostate-specific antigen (PSA) and the difference between clinical and PSA…”
Get more information

Flt3-Ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer by CIAVARRA, R. P, SOMERS, K. D, BROWN, R. R, GLASS, W. F, CONSOLVO, P. J. D, WRIGHT, G. L, SCHELLHAMMER, P. F

“…We assessed the in vivo efficacy of Flt3-ligand (Flt3-L) treatment in C57BL/6 mice bearing a well-established MHC class I-negative prostate carcinoma TRAMP-C1…”
Get full text

Surgery or brachytherapy revisited by Schellhammer, P F

Get full text

Effects of the calcium influx inhibitor carboxyamido‐triazole on the proliferation and invasiveness of human prostate tumor cell lines by Wasilenko, William J., Palad, Ann J., Somers, Kenneth D., Blackmore, Peter F., Kohn, Elise C., Rhim, Johng S., Wright, George L., Schellhammer, Paul F.

“…Aberrant cellular signaling is a central feature of malignant cells and a potential target for anti‐cancer therapy. Carboxy‐amido‐triazole (CAI) is a calcium…”
Get full text

Treatment of clinical local failure after radiation therapy for prostate carcinoma by Schellhammer, P F, Kuban, D A, el-Mahdi, A M

“…From a base population of 634 patients with prostate cancer treated by external beam therapy with a median followup of 8 years and 123 patients treated by…”
Get more information

Combined androgen blockade for the treatment of metastatic cancer of the prostate by Schellhammer, Paul F.

Get full text